A 12-week trial showed that subjects receiving 1 mg per day of AOD 9604 lost an average of 2.6 kilograms compared to 0.8 kilograms in the placebo group
Because 5-amino-1MQ is not a compounding-pharmacy-accessible substance and is not an FDA-approved therapy, the safety discussion is primarily about what physicians should tell patients asking about it, rather than about clinical monitoring parameters for active therapy
Preclinical work in obese murine models suggests that encapsulated 5-Amino-1MQ administration led to decreases in overall body weight and reductions in white adipose mass
Also, sadly enough, there also are many types of (chronic) diseases that require B12 injections, such as Pernicious Anemia, people with Crohns, celiac, and people with intestinal imbalances, such as intestinal tapeworms and excessive bacterial growth
their dysfunction leads to energy deficits that manifest as fatigue and slowed healing